- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.11. | Dynavax pays Vaxart $30M for oral COVID-19 vaccine program | ||
| 05.11. | FTC warns Novo that current Metsera offer structure may violate US merger law | ||
| 05.11. | Novo drops oncology ambitions, early-stage MASH prospects in ongoing R&D shake-up | ||
| 05.11. | Lilly pulls out of CNS portion of $960M RIPK1 inhibitor collab with Rigel | ||
| 05.11. | Novo Nordisk CEO 'feels' Danish pharma will bag Metsera at end of Pfizer bidding war | ||
| 05.11. | FDA rejects Biohaven approval request for troriluzole, triggering R&D cost cutting | ||
| 04.11. | Pfizer's parade of pipeline cuts: Seagen, BioNTech and MASH programs among 11 axed | ||
| 04.11. | Harmony halts genetic disease program following phase 3 Fragile X failure | ||
| 04.11. | Publisher's note: Questex acquisition supercharges Fierce portfolio with The Conference Forum, Versalinx Global Events | ||
| 04.11. | Novo, Pfizer's bidding war heats up with supercharged offers for Metsera | ||
| 04.11. | Prelude loses CMO, pauses SMARCA2 degraders and bags $60M from Incyte | ||
| 04.11. | Merck writes tale of 2 checks, bagging $700M from Blackstone and spending $150M to regain asset | ||
| 04.11. | Nuvation cancels plans to test brain cancer drug directly against Voranigo on FDA's advice | ||
| 04.11. | Celltrion looks beyond biosimilars with $744M pact for 2 preclinical autoimmune drugs | ||
| 03.11. | Tempero calls time on alcohol use disorder while mulling options, according to partner | ||
| 03.11. | uniQure's ballyhooed gene therapy for Huntington's hits FDA roadblock | ||
| 03.11. | Roche signs $2B pact to pilot Manifold Bio's shuttles to the brain | ||
| 03.11. | TScan lays off 30% of workforce, halts phase 1 solid tumor T-cell receptor trial | ||
| 03.11. | Neurocrine pens $880M deal with China's TransThera for red-hot immunology target | ||
| 03.11. | Pfizer sues Metsera over Novo's shock counter-offer, but obesity biotech stands firm | ||
| 31.10. | Biotech Graveyard | ||
| 31.10. | Cash-strapped Nanobiotix finds fresh way to source cash from J&J-partnered cancer drug | ||
| 31.10. | 4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy's phase 3 plans | ||
| 30.10. | Eli Lilly sidelines midstage prospect in another pain pipeline pivot | ||
| 30.10. | BMS culls 2 clinical programs, one from Mirati and another from Exscientia |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .